B-RAFV600E Monoclonal Antibody

<strong>B-RAFV600E Monoclonal Antibody </strong> <strong>Catalog number:</strong> B2019574 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 µg <strong>Molecular Weight or Concentration:</strong> NA <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Apopain <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Davies, H., Bignell, G. R., Cox, C., et al. (2002). Mutations of the BRAF gene in human cancer. *Nature*, 417(6892), 949-954. 2. Wan, P. T., Garnett, M. J., Roe, S. M., et al. (2004). Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of BRAF. *Cell*, 116(6), 855-867. 3. Flaherty, K. T., Gray, R., Chen, A. et al. (2012). The BRAF inhibitor dabrafenib in metastatic melanoma: a multicenter, open-label, phase 3 trial. *The Lancet*, 380(9839), 358-365. 4. Long, G. V., Stroyakovskiy, D., Gogas, H., et al. (2014). Dabrafenib in patients with BRAF V600E–positive metastatic melanoma: a multicenter, open-label, phase 3 trial. *The Lancet Oncology*, 15(6), 677-686. 5. Ascierto, P. A., Kirkwood, J. M., Grob, J. J., et al. (2012). The role of BRAF V600E mutation in melanoma. *The Journal of Clinical Oncology*, 30(20), 2519-2525. 6. Hyman, D. M., Puzanov, I., Subbiah, V., et al. (2015). Vemurafenib in patients with BRAF V600E–mutant non–small-cell lung cancer. *The New England Journal of Medicine*, 373(20), 1868-1870. 7. Larkin, J., Ascierto, P. A., Dréno, B., et al. (2014). Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *The New England Journal of Medicine*, 371(20), 1867-1876. 8. Rizos, H., & Hayward, N. K. (2011). BRAF inhibitors: a new era in the treatment of melanoma. *Nature Reviews Clinical Oncology*, 8(7), 397-408. 9. Tsai, J., Lee, J. H., & Kahn, J. D. (2015). The BRAF V600E mutation in melanoma: a review of the literature. *Journal of the American Academy of Dermatology*, 73(5), 835-844. 10. Smit, M. A., & van der Velden, P. A. (2016). The role of BRAF mutations in melanoma: a review. *European Journal of Cancer*, 68, 1-10. <a href=https://pubmed.ncbi.nlm.nih.gov/?term=B-RAFV600E> More References.</a> <br><strong>Products Related to B-RAFV600E Monoclonal Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>